- Investing.com
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Metrics to compare | IVX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIVXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −3.7x | −0.7x | |
PEG Ratio | 0.02 | −0.01 | 0.00 | |
Price/Book | 1.0x | 1.4x | 2.6x | |
Price / LTM Sales | - | 4.5x | 3.4x | |
Upside (Analyst Target) | - | 165.9% | 39.1% | |
Fair Value Upside | Unlock | 9.8% | 5.4% | Unlock |